For all the promise of RNA interference, its therapeutic reach has been frustratingly confined. The technology, which uses small-interfering RNA (siRNA) to silence disease-causing genes, has delivered breakthroughs for liver conditions. But the same biological machinery that makes the liver such an effective target also acts as a trap, sequestering these medicines and preventing them from reaching other organs. A new Cambridge-based biotech, Undecimal Bio, has launched with an $18 million seed round to pick that lock, starting with diseases of the kidney's blood vessels [Business Wire, October 2026].
The AI-Enabled Delivery Wedge
Undecimal's core bet is its proprietary platform, DELiveri, which it describes as an AI-enabled system for identifying molecular conjugates that can direct RNA medicines to defined cell types beyond the liver [Business Wire, October 2026]. The company treats the delivery challenge not as a singular chemistry problem, but as a data problem, a perspective echoed by co-founder Shaul Ilan [Shaul Ilan - ScionxBio | LinkedIn]. By screening and modeling vast libraries of potential targeting molecules, the platform aims to find the right keys to unlock specific tissues. The initial focus is renovascular diseases, conditions affecting the arteries that supply blood to the kidneys, representing a clear and clinically significant unmet need where current siRNA therapies cannot go [Business Wire, October 2026] [Clinical Renal Associates].
A Team Built on Serial Collaboration
The company is a spin-out from Eleven Therapeutics, an RNA-focused biotech, and carries forward a long-term partnership. The founding team pairs Dr. Yaniv Erlich, a computational biologist and former Chief Scientific Officer of MyHeritage DNA, with Shaul Ilan, described as his long-time partner [Business Wire, October 2026] [Base Pairs Episode 17.5] [Archie Muirhead - IQ Capital | LinkedIn]. This continuity is a signal to investors that the core scientific and strategic partnership has been stress-tested. The board reflects a blend of specialist biotech and deep tech capital, with seats held by lead investors 4BIO Capital and IQ Capital, alongside Harel Tech, and an observer role for Verve Ventures [Business Wire, October 2026].
| Role | Name | Notable Background |
|---|---|---|
| Co-Founder | Dr. Yaniv Erlich | Former CSO, MyHeritage DNA; former CEO, Eleven Therapeutics [Base Pairs Episode 17.5] [#51 - Science is exciting no matter where you do it - with Yaniv Erlich from Eleven Therapeutics] |
| Co-Founder | Shaul Ilan | Long-time partner of Dr. Yaniv Erlich [Archie Muirhead - IQ Capital |
| Lead Investor (Board) | 4BIO Capital & IQ Capital | Co-led the $18 million seed round [Business Wire, October 2026] |
The Roadmap and Its Inherent Risks
The seed capital is earmarked for expanding the DELiveri platform, advancing internal renovascular programs, and growing the team across its labs in Cambridge and Tel Aviv [Business Wire, October 2026]. A significant early traction signal is the company's report of "several research collaborations with big pharma companies," though the partners remain undisclosed [Business Wire, October 2026]. This suggests validated interest from potential future licensors, a critical path for a platform biotech. The primary risks are not conceptual but executional.
- Technical validation. The AI platform's predictions must be borne out by in vivo data. Identifying a conjugate is one step; proving it safely and effectively delivers a therapeutic payload in a complex disease model is another, and the company has not yet published peer-reviewed data on this front.
- Competitive landscape. While no direct competitors are named in the sources, the field of targeted RNA delivery is crowded with well-funded players. Undecimal's success hinges on the unique efficacy of its DELiveri-identified conjugates.
- Regulatory pathway. Renovascular diseases, while having clear need, can involve heterogeneous patient populations. Designing a clinical trial that clearly demonstrates a delivery platform's advantage adds a layer of complexity to the already arduous drug development process.
For patients with renovascular disease, the current standard of care is often a patchwork of managing secondary symptoms like hypertension with generic medications, or invasive procedures like angioplasty to open narrowed arteries. These approaches address the downstream consequences of poor blood flow but do not target the underlying pathological gene expression driving the disease process. Undecimal's ambition is to change that equation, offering a precise, genetically targeted therapy delivered directly to the affected vasculature. The next twelve months will be about translating its AI-driven platform from promising data into biological proof, moving one step closer to freeing RNA medicine from its hepatic cage.
Sources
- [Business Wire, October 2026] Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery | https://www.businesswire.com/news/home/20261013517369/en/Undecimal-Bio-launches-with-$18-million-oversubscribed-Seed-financing-to-address-liver-trap-in-siRNA-therapeutic-delivery
- [CTech, October 2026] Undecimal Bio raises $18 million Seed to tackle a key obstacle in RNA medicines | https://www.calcalistech.com/ctechnews/article/hjyfaviszg
- [Clinical Renal Associates] Renovascular disease primarily affects the renal arteries, which deliver blood to the kidneys | https://clinicalrenal.com/conditions/renovascular-disease/
- [Base Pairs Episode 17.5] Special interview with Yaniv Erlich | https://www.cshl.edu/podcasts/episode-17-5-special-interview-with-yaniv-erlich/
- [#51 - Science is exciting no matter where you do it - with Yaniv Erlich from Eleven Therapeutics] Podcast interview | https://www.macademiapodcast.com/51-science-is-exciting-no-matter-where-you-do-it-with-yaniv-erlich-from-eleven-therapeutics/
- [Shaul Ilan - ScionxBio | LinkedIn] LinkedIn profile | https://www.linkedin.com/in/shaul-ilan-8064bb51/
- [Archie Muirhead - IQ Capital | LinkedIn] LinkedIn post | https://www.linkedin.com/in/omerz213/